文献速递血栓与止血

肾脏Klotho蛋白通过抑制Bcl-xL泛素化与降解保障晚期慢性肾脏病中的血小板寿命

Renal Klotho safeguards platelet lifespan in advanced chronic kidney disease through restraining Bcl-xL ubiquitination and degradation.
PubMed 文献 · J Thromb Haemost · 2022-09-23

该研究基于队列研究、CKD小鼠和Klotho缺陷CKD小鼠,探讨晚期CKD中血小板稳态变化及其与肾脏Klotho缺乏的关联。发现晚期CKD患者和小鼠血小板计数下降且与循环Klotho水平正相关,机制上UBE2O介导Bcl-xL泛素化降解,而肾脏分泌的可溶性Klotho蛋白限制血小板氧化应激从而维持Bcl-xL表达和血小板寿命。

要点

  • 晚期CKD患者和小鼠模型血小板计数下降,且与循环Klotho水平正相关。
  • 晚期CKD诱导的血小板氧化应激通过p38MAPK促进Bcl-xL磷酸化,增强UBE2O对Bcl-xL的结合与降解。
  • 肾脏分泌的可溶性Klotho蛋白限制血小板氧化应激,维持Bcl-xL表达和血小板寿命。

核心结论

  • 晚期CKD中血小板计数下降的机制涉及肾脏Klotho缺乏导致血小板氧化应激增强、Bcl-xL降解加速和血小板寿命缩短,肾脏Klotho是血小板寿命的远程调节因子,并提供潜在治疗选择。

研究设计与样本

  • 研究基于队列研究以及CKD小鼠和Klotho缺陷CKD小鼠模型,采用流式细胞术和血小板转移检测血栓生成和血小板寿命,通过蛋白质组学、流式细胞术、蛋白质印迹和免疫沉淀探索机制。

主要发现

  • 晚期CKD患者和小鼠模型均出现血小板计数下降,且与循环Klotho水平正相关。
  • UBE2O作为泛素连接酶调控血小板中Bcl-xL的泛素化和降解,晚期CKD诱导的血小板氧化应激刺激p38MAPK促进Bcl-xL磷酸化,促进UBE2O与Bcl-xL结合及后续Bcl-xL降解。
  • 晚期CKD中血小板寿命缩短,导致血小板计数下降,而肾脏分泌的可溶性Klotho蛋白限制血小板氧化应激,维持Bcl-xL表达和血小板寿命。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thrombosis and hemorrhage as two opposite pathologies are prevalent within the chronic kidney disease (CKD) population. Platelet homeostasis, which positions centrally in their pathogenesis, varies among the CKD population, while the underlying mechanism is poorly understood. OBJECTIVE: To investigate the change character and mechanism of platelet homeostasis in CKD and its association with renal Klotho deficiency. METHODS: The change character of platelet homeostasis and its association with renal Klotho deficiency were determined based on a cohort study as well as CKD mice and Klotho-deficient mice with CKD. The effects on thrombopoiesis and platelet lifespan were examined by flow cytometry and platelet transfer. The underlying mechanism was explored by proteomics, flow cytometry, western blot, and immunoprecipitation. RESULTS: We show that platelet count declines both in patient and mouse models with advanced CKD (Adv-CKD) and is positively associated with circulating Klotho levels. Mechanistically, we identify that ubiquitin ligase UBE2O governs Bcl-xL ubiquitination and degradation in platelets, whereas Adv-CKD-induced oxidative stress in platelets stimulates p38MAPK to promote Bcl-xL phosphorylation, which facilitates UBE2O binding to Bcl-xL and subsequent Bcl-xL degradation. Consequently, platelet lifespan is shortened in Adv-CKD, culminating in platelet count decline. However, kidney-secreted soluble Klotho protein restricts oxidative stress in platelets, thereby preserving Bcl-xL expression and platelet lifespan. CONCLUSIONS: Our findings uncover the mechanism of platelet count decline in Adv-CKD and identify renal Klotho as a long-range regulator of platelet lifespan, which not only provide a molecular mechanism underlying CKD-associated thrombocytopenia and hemorrhage but also offer a promising therapy choice.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Lan Q, Du C, Xiong J, et al. Renal Klotho safeguards platelet lifespan in advanced chronic kidney disease through restraining Bcl-xL ubiquitination and degradation. J Thromb Haemost. 2022. PMID: 36087344. doi:10.1111/jth.15876

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。